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Converging evidence indicates that major depressive disorder (MDD) and meta-
bolic disordersmight bemediated by shared (patho)biological pathways. However,
the converging cellular and molecular signatures remain unknown. Here, we inves-
tigatedmetabolic dysfunction on a systemic, cellular, andmolecular level in unmed-
icated patients with MDD compared with matched healthy controls (HC). Despite
comparable BMI scores and absence of cardiometabolic disease, patients with
MDD presented with significant dyslipidemia. On a cellular level, T cells obtained
from patients with MDD exhibited reduced respiratory and glycolytic capacity.
Gene expression analysis revealed increased carnitine palmitoyltransferase IA
(CPT1a) levels in T cells, the rate-limiting enzyme for mitochondrial long-chain fatty
acid oxidation. Together, our results indicate metabolic dysfunction in unmedi-
cated, non-overweight patients with MDD on a systemic, cellular, and molecular
level. This evidence for reduced mitochondrial respiration in T cells of patients
with MDD provides translation of previous animal studies regarding a putative
role of altered immunometabolism in depression pathobiology.Hamburg, Germany
3Charité –
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Major depressive disorder (MDD) is a highly prevalent psychiatric disease associated with a substantial dis-
ease burden (Whiteford et al., 2013) and increasedmortality (Machado et al., 2018; Plana-Ripoll et al., 2019).
A large body of literature indicates that MDD is associated with alterations in several (neuro)biological sys-
tems, including dysfunction in metabolic pathways (Otte et al., 2016). Indeed, comorbid depression is
particularly common in patients with cardiometabolic disorders (Gold et al., 2020) and accumulating evi-
dence from large-scale epidemiological studies has revealed a bidirectional association between MDD
and an increased risk for heart disease (Nicholson et al., 2006), diabetes (Mezuk et al., 2008), and metabolic
syndrome (Pan et al., 2012). This seems to extend to subclinical metabolic dysregulation, as a metabolo-
mics analysis in 5,283 cases and 10,145 healthy controls revealed evidence for a distinct profile of dyslipi-
demia in MDD (Bot et al., 2020). These associations were consistent across sex, age, and body mass index
(BMI) strata, indicating that they are unlikely to be epiphenomena of medical comorbidities in MDD.
Converging evidence indicates that the link between metabolic dysfunction and MDD could be mediated
via common (patho)biological pathways. For example, metabolic diseases and MDD have been shown to
share genetic risk factors, as demonstrated by a risk variant overlap between BMI and MDD, particularly in
atypical depression (Milaneschi et al., 2017). Of note, these mainly comprise genes that are involved in in-
flammatory pathways.
Given the importance of inflammation in the pathophysiology of MDD (Miller and Raison, 2016) and the
crucial role of metabolic programming for immunity (Buck et al., 2017), it seems biologically plausible
that metabolic dysfunction in general, and altered immunometabolism in particular, could contribute to
the pathogenesis of depression (Milaneschi et al., 2020). In line with this notion, recent studies using animal
models have provided direct evidence for a causal role of metabolic dysfunction in depression: for
example, diet- or genetically induced obesity has been shown to induce depression-like behavior iniScience 24, 103312, November 19, 2021 ª 2021 The Authors.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table 1. Sample characteristics
MDD (n = 28) HC (n = 28) Test statistics p Valuea
Age, mean years (SD) 32.2 (11.7) 32.2 (10.5) T(df=27) = 0 >.99
BMI, mean kg/m2 (SD) 24.5 (3.4) 23.9 (3.4) T(df=27) = 1.32 .20
% Females (n) 75 (21) 75 (21) X2(df=1) = 0 >.99
% Current smokers (n) 25 (7) 25 (7) X2(df=1) = 0 >.99
MADRS, mean score (SD) 25.3 (5.4) 0.9 (1.4) T(df=27) = 25.09 <.01
BDI-II, mean score (SD) 30.3 (7.0) 2.3 (3.1) T(df=27) = 17.76 <.01
BAI, mean score (SD) 21.9 (13.2) 3.6 (3.1) T(df=27) = 6.99 <.01
CTQ total score (SD) 40.8 (15.5) 35.1 (11.3) T(df=27) = 1.42 .17
% MDD subtype (n) 64.3 (18) – –
% Melancholic (n) 60.7 (17) – –
% Atypical (n) 3.7 (1) – –
BAI, Beck Anxiety Inventory; BDI-II, Beck Depression Inventory II; BMI, body mass index; CTQ, Childhood Trauma Question-
naire; HC, healthy control; MADRS, Montgomery-Asberg Depression Rating Scale; MDD, major depressive disorder.
Unless specified otherwise, values represent mean (standard deviation).




Articlemice (Ogrodnik et al., 2019). Of note, this effect was independent of weight gain but was mediated via in-
flammatory mechanisms. On a cellular level, in another study, chronic stress caused T cell-specific distur-
bances of mitochondrial fusion and respiration (Fan et al., 2019). Intriguingly, transfer of these T cells to
non-stressed recipient mice was sufficient to cause anxiety/depression-like behavior (Fan et al., 2019).
However, whether these findings can be translated to humans remains unknown. Thus, although an
impaired mitochondrial function in a number of tissues and cell populations, including in the central
nervous system (CNS) (Pei and Wallace, 2018), may play a role in depression pathobiology, studying these
aspects in the immune system, and specifically in T cells, might be particularly relevant. In the present study,
we therefore examined metabolic dysfunction in unmedicated patients with MDD (but without metabolic
or cardiovascular disease) on a systemic, cellular and molecular level, compared with healthy controls (HC)
individually matched for important potential confounders (age, sex, BMI, smoking status).
RESULTS
An overview of the clinical and demographic characteristics of the study sample is provided in Table 1
(individual patient data are provided in Table S2).
Patients with MDD display subtle signs of systemic metabolic dysfunction
Despite close matching for sex, age, BMI, and smoking status, as well as the absence of cardiometabolic
disorders in both groups, patients with MDD exhibited subtle signs of metabolic dysfunction compared to
healthy controls (HC) (Figure 1). Specifically, patients with MDD showed a higher LDL/HDL ratio (Figure 1A)
and a higher waist/hip ratio (WHR) (Figure 1B). Systolic and diastolic blood pressure readings were similar
between the groups (Figures 1C and 1D). Group differences in LDL/HDL ratio and WHR remained signifi-
cant in secondary analyses using Bonferroni correction for multiple testing. Serum metabolites, measured
by mass spectrometry-based metabolomics and lipidomics in order to identify further global metabolic
signatures in patients with MDD, did not reveal any additional differences between MDD and HC, at least
none large enough to be detected with metabolome-wide correction in our sample (Figure 1E).
Key parameters of mitochondrial respiration and glycolytic activity are reduced in T cells
from patients with MDD
On a cellular level, we observed pronounced impairment of major metabolic readouts in MDD. T cells
(defined by CD3 positivity) from patients with MDD exhibited lower levels of oxygen consumption (OCR)
(Figure 2A) and lower extracellular acidification rates (ECAR) (Figure 2B), indicative of impaired mitochon-
drial respiration and decreased glycolytic capacity, especially under cellular stress (Figure 2E). In the pri-
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Figure 1. Systemic metabolic imbalance in MDD
(A–D) Serum lipids (HDL, high density lipoprotein and LDL, low density lipoprotein, here shown as LDL/HDL ratio) (A),
waist/hip ratio (B), as well as systolic (C) and diastolic (D) blood pressure levels were determined in 28 patients with MDD
and matched HC. Raw data and group median are shown. Wilcoxon signed-rank test was used to compare groups.
(E) Serum metabolomics group comparison in HC versus MDD. In total, 3,511 features were detected by liquid and gas
chromatography-mass spectrometry. Dashed lines on the x axis indicate threshold values separatingmetabolites with >2-
fold expression in MDD versus HC (+1) or <0.5-fold expression in MDD versus HC (1). The dotted line on the y axis




Articledecreased basal respiration, lower ATP production, and diminished spare respiratory capacity (Figure 2C).
Moreover, basal respiration was to a large extent coupled to ATP production with almost no H+ (proton)
leak (Figure 2D). With the exception of coupling efficiency, all of these markers were also
significantly different after correction for multiple comparisons in the secondary analyses. In monocytes
(Figure S2) only one readout (coupling efficiency) was significantly different between MDD and controls
in the primary analysis, and this difference was no longer significant after correcting for multiple compar-
isons. Together, these data suggest a cell-specific reduction of mitochondrial respiration in T cells of
patients with MDD.
In order to explore the link of these markers with clinical phenotype, we examined associations of systemic and
T cell markers with clinician-rated depression severity as measured by the Montgomery-Asberg Depression
Rating Scale (MADRS) (Montgomery and Asberg, 1979), with a higher MADRS score indicative of more severe
depression (Figure 2F). Among systemic markers, only LDL/HDL ratio showed significant positive correlation
with twoMADRS items, inner tension and sleep. In contrast, correlations of clinical phenotype weremore robust
for all cellular markers, where basal respiration, ATP production, and spare respiratory capacity of T cells were
significantly negatively correlated with all MADRS items, except for sleep.
Reduced mitochondrial respiration in patients with MDD is unlikely to be explained by global
shifts in T cell phenotype or immune senescence/exhaustion
Different T cell subpopulations have distinct metabolic profiles, depending on their differentiation stage,
activation status, or cellular senescence/exhaustion (Geltink et al., 2018). To rule out the possibility that our
observed changes in mitochondrial respiration weremerely the result of an over- or underrepresentation of
certain T cell subpopulations in patients with MDD, we conducted flow cytometric phenotyping analyses.
Among all the phenotypes tested, only one marker (KLRG1) showed significant group differences between
MDD and HC in the primary analysis; however, this did not survive adjustment for multiple testing in sec-
ondary analyses (Figure 3). Overall, group differences in T cell differentiation or senescence/exhaustion are
thus unlikely to explain the pronounced differences in T cell metabolism.
Decreasedmitochondrial respiration in patients withMDD is not secondary to impairments in
antiviral immunity
Growing evidence suggests an association betweenmetabolically exhausted T cells and chronic infections.
Moreover, prior work has shown that patients with MDD have a higher risk for persistent herpes virusiScience 24, 103312, November 19, 2021 3
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Figure 2. Decreased mitochondrial respiration in T cells of patients with MDD
(A and B) To quantify mitochondrial respiration (A) as well as glycolytic activity (B) of CD3+ T cells from 28 patients with
MDD and 28 matched HC different modulators of respiration were added sequentially to the cells (see also Figure S1) and
the oxygen consumption rate (OCR) as well as the extracellular acidification rate (ECAR) were determined over time in a
Seahorse XFe96 Analyzer (mean G SEM is shown, all assays run in three to five replicates for each subject).
(C and D) The main parameters of mitochondrial respiration (basal respiration, ATP production, and spare respiratory
capacity) (C) as well as the coupling efficiency expressed as the % of basal respiration coupled to ATP production (CE%)
(D) are shown. See also Figure S1 for further information regarding the calculation of these parameters from OCR
measurements. Individual patient data and median are shown. Wilcoxon signed-rank test was used to compare groups.
(E) OCR and ECAR values under baseline and stressed conditions (after addition of Oligomycin and FCCP) were plotted
against each other to visualize the energy phenotype of the cells (mean G SEM shown).
(F) Spearman rank correlations of systemic and T cell markers with individual MADRS items. Circle sizes indicate
magnitude of correlation, color shading depicts magnitude and direction of correlation (Spearman’s rho, see legend).
Asterisks were added to the circles if p < 0.005.
Oligomycin, ATP synthase inhibitor; carbonyl cyanide-4(trifluoromethoxy) phenylhydrazone (FCCP), uncoupling agent;
Rotenone/Antimycin A, complex I/III inhibitors; BR, basal respiration; CRP, C-reactive protein; IL-6, interleukin 6; LDL/
HDL, low/high density lipoprotein; MADRS, Montgomery-Asberg Depression Rating Scale; SRC, Spare Respiratory
Capacity; TNF, tumor necrosis factor; WHR, waist/hip ratio. Individual patient data for the Seahorse readouts presented
here are provided in the supplementary data file, Data S1.
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Figure 3. T cell phenotype and senescence/exhaustion markers in MDD
(A–D) PBMCs from patients with MDD andmatched HC were examined by flow cytometry. CD4+ (upper panel) and CD8+ T cell subpopulations (lower panel) were
analyzed for the expression of markers classifying differentiation (CD45RA, CCR7; n = 25) (A), chemokine receptors (CXCR3, CCR6, CCR4; n = 25) or regulatory T cell
markers (CD25, CD127; n = 22) (B), markers indicative of exhaustion or senescence (PD-1, KLRG1, CD57; n = 19–20) (C) or inhibitory receptors (CTLA-4, LAG-3, Tim-3;
n = 20) (D). Naive/Memory subpopulations were defined as TNaive (CCR7
+/CD45RA+), TEM (CCR7
/CD45RA), TCM (CCR7
+/CD45RA), and TEMRA (CCR7
/
CD45RA+). T helper cell subsets were defined as Th1 (CXCR3+/CCR6), Th2 (CXCR3/CCR6/CCR4+), Th17 (CXCR3/CCR6+/CCR4+), and Th1/Th17 cells (CXCR3+/
CCR6+) (n = 25). For the analysis of inhibitory receptors, PBMCs were stimulated with 10 mg/mL of a-CD3 and 1 mg/mL a-CD28 for 48 h. Median and interquartile




Articleinfections like Epstein-Barr virus (EBV) or cytomegalovirus, both before and after onset of depressive symp-
toms (Andersson et al., 2016). We therefore examined whether the observed reduction in mitochondrial
respiration of T cells in patients with MDD could be linked to differences in antiviral immune responses.
We chose EBV (pooled EBNA-1, LMP2a and BZLF1 peptide pools) as an exemplary antigen as we expected
90%–95% seropositivity in adults. As control antigen, MP65 fromCandida albicanswas applied, a yeast-like
fungus that occurs as a facultative pathogenic commensal on skin and mucosal surfaces and has so far not
been linked to the occurrence of MDD. Median frequency of EBV- and MP65-reactive T cells was similar in
both groups (4 out of 10,000 CD4+ T cells for EBV and 3 out of 10,000 for MP65) (Figure S3). As expected for
a recall antigen, CD45RA T cells, i.e., bona fide memory T cells, made up almost 100% of the EBV-reactive
T cell population in both HC and patients with MDD. The same was true for the control antigen MP65. An-
tigen-specific T cells obtained from both study groups were capable of producing comparable amounts of
interferon gamma (IFN-g) in response to the viral and the fungal stimulus. Moreover, we could not detect
any significant differences with regard to the expression of exhaustion markers (PD-1) or markers indicative
of cell senescence (CD57) that are typically upregulated in chronic viral infections with continuous antigen
exposure. Together, these data suggest that metabolic alterations in MDD are not secondary to group dif-
ferences in antiviral immunity, at least for common persistent infections such as EBV.
Cell-specific expression of key metabolic regulators
Finally, we explored if the transcriptional profile of T cells from patients with MDD indicated metabolic
reprogramming. Using targeted cell-specific gene expression analysis by qPCR, we found that T cells of
patients with MDD exhibited significantly higher levels of carnitine palmitoyltransferase 1A (CPT1a), which
encodes a rate-limiting mitochondrial enzyme of long-chain fatty acid (FA) oxidation (Figure 4A). However,
expression of SLC2A1, encoding the membrane glucose transporter type 1 (GLUT1), the main glucose
transporter during T cell activation, and a key inflammatory cytokine (TNF) was unaltered in patients with
MDD compared with controls (Figures 4B and 4C). This effect was more pronounced in T cells but still
detectable in monocytes (Figure S4).
To explore additional shifts, we conducted post hoc analyses of cell-specific expression of key metabolic
































































































































Figure 4. Expression of key regulators of cellular metabolism in T cells of patients with MDD
(A–C) mRNA expression levels of CPT1a (A), SLC2A (encoding GLUT1) (B), and TNF (C) in T cells of patients with MDD (n = 25)
compared with matched controls (n = 25). Gene expression is shown as fold change relative to housekeeping genes (TBP and
IPO8). Individual patient data and median are shown. Wilcoxon signed-rank test was used to compare groups.
(D-E) The numbers of metabolome-wide significant correlations (of 3,511 detected features) are shown for CD3 and CD14
cellular mitochondrial readouts (BR, basal respiration; ATP, ATP production; SR, spare respiratory capacity) (D). Top
known metabolites significantly correlated with CD3 CPT1a expression (E). CPT1a, carnitine palmitoyltransferase 1 A;




Articleperipheral blood mononuclear cells (PBMCs) available for analysis. The following six key regulators (as
markers of different major metabolic pathways) were chosen: CPT1a (key regulator of FA oxidation),
GLUT1 (glucose uptake), Glucose-6-phosphate-dehydrogenase (G6PD; oxidative phosphorylation), Hexo-
kinase 1 (HK1; glycolysis), Isocitrate dehydrogenase 2 (IDH2; tricarboxylic acid cycle), and Peroxiredoxin 2
(PRDX2; antioxidant). Our results showed no major differences between MDD and HCs in geometric mean
fluorescence intensities of these proteins, at least none that were large enough to be detected in this small
subset. Also, no significant correlations betweenmetabolic proteins and CD3 and CD14 Seahorse readouts
were found after correction for multiple comparisons (Figure S5).
In order to explore potential correlates of altered cellular metabolism and gene expression, we investi-
gated if CD3 and CD14 cellular readouts correlated with global serum metabolites. Results showed
CPT1a gene expression in T cells was the only one with substantial correlations, with 164 serummetabolites
significantly associated after metabolome-wide correction (Figure 4D), including acylglycerols among the
top hits (Figure 4E).DISCUSSION
The current study examined metabolic dysfunction in unmedicated and otherwise healthy MDD and HC.
Our results showed that MDD is characterized by metabolic dysfunction on a systemic, cellular, and molec-




ArticleOn a systemic level, we have confirmed findings of a recent hypothesis-free metabolomics study suggest-
ing dyslipidemia in MDD (Bot et al., 2020) that is independent of obesity, sex, age, or other clinical
descriptors and may thus be an early manifestation of MDD and potentially involved in its pathobiology.
This phenomenon could provide a biological pathway for the significantly elevated risk of cardiometabolic
disease in patients with depression.
On a cellular level, we obtained evidence for impaired mitochondrial respiration specifically in T cells of
patients with MDD. Our analyses also showed that these alterations are unlikely to simply reflect an
epiphenomenon of shifts in T cell differentiation, activation, or senescence/exhaustion. This finding cor-
roborates and extends existing evidence of mitochondrial dysfunction in depression (Allen et al., 2018),
which has also been described outside the CNS, e.g., in platelets (Hroudova et al., 2013) and PBMCs (Kar-
abatsiakis et al., 2014; Boeck et al., 2018). Of importance, the metabolic profiles of T cells seen in our
MDD cohort bear striking similarity to those reported for T cells obtained from mice after chronic stress
(Fan et al., 2019). In this previous study, transfer of these T cells to non-stressed mice in the animal model
was sufficient to elicit depression/anxiety-like behavior (Fan et al., 2019), indicating that they could be
causally involved in the pathogenesis of depression. Here, our data, obtained with the same readout sys-
tem for T cell metabolism, provide a translational link from the experimental mouse model to major
depression in humans. One intriguing observation here was that the main mitochondrial readouts in
T cells (basal respiration, spare respiratory capacity, ATP production) did not show strong correlations
with levels of systemic metabolites, using an unbiased metabolomics approach. Although one has to
be careful with such interpretations of sequence or cause and effect from purely cross-sectional, obser-
vational data, this is in line with the notion that reduced mitochondrial respiration in T cells might be a
primary event rather than simply an epiphenomenon. This could have some relevance from a therapeutic
perspective; modulating cellular processes in the peripheral immune system, as compared with the CNS,
might be easier to achieve.
On a molecular level, T cells from patients with MDD showed increased mRNA levels of CPT1a, the rate-
limiting enzyme for mitochondrial FA oxidation. CPT1a codes for carnitine palmitoyltransferase 1A, which
regulates the transport of long-chain FAs across the inner mitochondrial membrane and makes them avail-
able for FA oxidation. Therefore, increased levels of CPT1a gene expression and unaltered levels of
SLC2A1 (encoding GLUT1) at the same time might be suggestive of an increased reliance on lipolysis
and/or ß-oxidation, rather than glycolysis for metabolism; however, we did not measure this directly.
The observed correlations of CPT1a expression in T cells with many metabolites (including acylglycerols
among the top hits) may indicate that CPT1a upregulation is more likely an epiphenomenon of systemic
metabolic changes in MDD, although we obviously cannot infer cause and effect from our observational
data. Ultimately, this finding could add to the emerging evidence that targeting cellular metabolism offers
a potential therapeutic pathway in depression: A study in an animal model of depression (Morkholt et al.,
2017) has provided evidence that chronic stress increases CPT1a expression both in the CNS and in the im-
mune system and that treatment with etomoxir decreases depression-like behavior in rats. Etomoxir has
been in clinical development for cardiometabolic disorders (diabetes and heart failure) but was discontin-
ued owing to hepatotoxicity. Moreover, recent evidence has suggested that etomoxir may exert immuno-
modulatory properties on T cells (Raud et al., 2018), which are independent of CPT1a, so caution is
warranted.
A recent metabolomics study in the general population (Zacharias et al., 2021) found decreased serum
levels of laurylcarnitine in individuals with elevated levels of depressive symptoms. This metabolite is
involved in the transport of (long-chain) FAs from the cytosol to mitochondria for subsequent b-oxidation.
Together with our data, this supports the notion of altered FA oxidation and/or mitochondrial activity in
depression.
In sum, our study provides evidence for metabolic dysfunction on a systemic, cellular, andmolecular level in
MDD, extending previous mechanistic insights from animal models and lending further support to the
notion of depression as a putative ‘‘immunometabolic’’ disease.Limitations of the study
Several limitations of our study should be noted. First, although our analyses were controlled for medical




ArticleHowever, given that our results on systemic metabolic markers closely mirror findings from larger studies of
MDD versus HC (i.e., evidence for lower HDL and higher LDL), we are confident that our results in this rela-
tively small sample are generalizable to other MDD patient populations. Nevertheless, our findings need
replication in larger, and particularly in longitudinal studies. We have carefully explored alternative expla-
nations for changes in cellular metabolism (including altered immune cell composition, differentiation,
senescence/exhaustion, and antiviral T cell immunity), and it appears that altered cellular metabolism
can be observed without changes in these parameters.
Although the study groups were matched for sex and age, our sample was predominantly female, as would
be expected for MDD. Owing to the low number of males, our study was not powered to test sex differ-
ences in mitochondrial respiration. Such analyses should thus be conducted in larger samples to examine
generalizability of our findings to both sexes or putative sex differences. For anyone interested in sepa-
rately analyzing our main readouts by sex, we have provided patient-level information on sex in Table S2
and Data S1.
In order to unravel the implications of reduced mitochondrial respiration in MDD, future studies should
directly test different cellular functions putatively driven by altered immunometabolism in MDD. Unfortu-
nately, for the present study, we were limited with regard to the amount of biological material that could be
obtained from each participant (e.g., acceptable limits for blood draw volumes as set out in the ethics re-
view and informed consent procedures). Thus, although we conducted extensive experiments to analyze
mitochondrial respiration and key metabolic processes and proteins/enzymes as well as relevant control
readouts, we did not directly assess potential group differences in a range of additional associated cellular
functions. Based on our results, future studies should expand our study by directly probing FA uptake and
transport in T cells (e.g., CD36, FA-binding proteins). In addition, FA oxidation assays could provide in-
sights into whether the observed increase in CPT1a also reflects a higher ability of T cells for FA oxidation.
Moreover, it would be relevant to better understand functional and structural changes within the cells, such
as quantification of mitochondrial mass (e.g., by MitoTracker labeling), visualization of mitochondrial fusion
and fission, assessment of oxygen consumption in isolated mitochondria, and measurement of reactive
oxygen species (e.g., via MitoSOX). Changes in the mitochondrial membrane potential were not measured
in our study but could, for example, be estimated by the use of fluorescent dyes like tetramethylrhodamine,
methyl ester (TMRM) or 5,50,6,60-tetrachloro-1,10,3,30-tetraethyl-imidacarbocyanine iodide (JC-1) in future
studies, as these markers accumulate in healthy cells with intact mitochondrial membrane potential (Perry
et al., 2011). Such measurements might further substantiate findings on reduced mitochondrial respiration
(and ATP production in particular) in T cells of patients with MDD as the transmembrane electrochemical
gradient is the driver of ATP synthesis.
It should be noted that the mitochondrial alterations we have detected in peripheral immune cells, and in
T cells specifically, do not necessarily reflect mitochondrial aberrations in other cells and tissues with rele-
vance for MDD, most notably the CNS. In fact, mitochondrial function is typically regulated in a highly cell-
and tissue-specific fashion (Fernández-Vizarra et al., 2011). However, mitochondrial dysfunction in T cells is
interesting in its own right owing to their putative role in the pathogenesis of depression-like symptoms as
animal models have demonstrated (Fan et al., 2019). Thus, future studies may combine analyses of key
mitochondrial parameters in central and peripheral (immune) cells and tissues in animal models of
depression to expand our knowledge on the influence of an altered peripheral immunometabolism on
the CNS in MDD.
We have previously reported that certain shifts in the T cell compartment can be detected in MDD, at least
in treatment-naı̈ve patients without any psychiatric comorbidity, specifically with regard to the expression
of chemokine receptors (CXCR3, CCR6) (Patas et al., 2018). We could not replicate this in the present cohort
(where some patients, although untreated at the time of study, had previously been treated with antide-
pressants). Thus, we cannot rule out that there may be subtle shifts in T cell subset compositions (e.g., signs
of CD4 T cell exhaustion/senescence as indicated by KLRG1 expression) in MDD. Larger studies are thus
needed to explore this further.
Finally, the sequence of metabolic, immunological, and other (neuro)biological substrates of depres-
sion remains incompletely understood and should be explored in detail in appropriate animal models




Articletrials. For example, we are currently conducting a randomized trial of add-on statins in patients with
comorbid MDD and obesity, where cellular and molecular substrates of mitochondrial function are
monitored as secondary endpoints (see Otte et al., 2020). This and similar approaches will help to
further dissect the nature of the relationship between depression, metabolic dysfunction, and
immunometabolism.STAR+METHODS
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Antibodies
Brilliant Violet 421 anti-human CD3 (OKT3) Biolegend Cat# 317344; RRID:AB_2565849
Brilliant Violet 510 anti-human CD8 (SK1) Biolegend Cat# 344732; RRID:AB_2564624
FITC anti-human HLA-DR (LN3) Biolegend Cat# 327006; RRID:AB_893569
PE anti-human CD 197 (CCR7) (G043H7) Biolegend Cat# 353204; RRID:AB_10913813
PerCPCy5.5 anti human CD4 (RPA-T4) Biolegend Cat# 300530; RRID:AB_893322
PE/Cy7 anti human CD45RA (HI100) Biolegend Cat# 304126; RRID:AB_10708879
APC anti-human CD38 (HB-7) Biolegend Cat# 356606; RRID:AB_2561902
PE anti-human CD183 (CXCR3) (G025H7) Biolegend Cat# 353706; RRID: AB_10962912
PE/Cy7 anti-human CD196 (CCR6) (G034E3) Biolegend Cat# 353418; RRID:AB_10916518
APC anti-human CD194 (CCR4) (L291H4) Biolegend Cat# 359408; RRID:AB_2562429
Brilliant Violet 421 anti-human FOXP3 (206D) Biolegend Cat# 320124; RRID:AB_2565972
Brilliant Violet 510 anti-human CD3 (SK7) Biolegend Cat# 344828; RRID:AB_2563704
PE anti-human CD279 (PD-1) (EH12.2H7) Biolegend Cat# 329906; RRID:AB_940483
PerCP/Cyanine5.5 anti-human IFN-g (4S.B3) Biolegend Cat# 502526; RRID:AB_961355
APC anti-human CD57 (HNK-1) Biolegend Cat# 359610; RRID:AB_2562757
Brilliant Violet 421 anti-human CD185
(CXCR5) (J252D4)
Biolegend Cat# 356920; RRID:AB_2562303
PE anti-human CD25 (M-A251) Biolegend Cat# 356104; RRID:AB_2561861
APC anti-human CD127 (IL-7Ra) (A019D5) Biolegend Cat# 351316; RRID:AB_10900804
APC/Cyanine7 anti-human CD8a (RPA-T8) Biolegend Cat# 301016; RRID:AB_314134
Brilliant Violet 421 anti-human CD366 (Tim-3)
(F38-2E2)
Biolegend Cat# 345008; RRID:AB_11218598
FITC anti-human CD223 (LAG-3) (11C3C65) Biolegend Cat# 369308; RRID:AB_2629751
PE anti-human KLRG1 (MAFA) (SA231A2) Biolegend Cat# 367712; RRID:AB_2572157
APC anti-human CD152 (CTLA-4) (BNI3) Biolegend Cat# 369612; RRID:AB_2632874
APC-Vio 770 anti-human CD4 (VIT4) Miltenyi Biotec Cat# 130-096-652; RRID:AB_2660925
VioGreen CD8 anti-human (BW135/80) Miltenyi Biotec Cat# 130-096-902; RRID:AB_2660905
VioGreen CD20 anti-human (REA780) Miltenyi Biotec Cat#: 130-111-532; RRID:AB_2656069
VioGreen CD14 anti-human (Tük4) Miltenyi Biotec Cat# 130-096-875; RRID:AB_2660175
FITC CD154 anti-human (5C8) Miltenyi Biotec Cat# 130-096-233; RRID:AB_10830229
CD40 Antibody, anti-human, pure-functional
grade (HB14)
Miltenyi Biotec Cat# 130-094-133; RRID:AB_10839704
Alexa Fluor 488 Anti-CPT1A (8F6AE9) abcam Cat# ab171449; RRID:AB_2714024
Anti-IDH2 (EPR7577) abcam Cat# ab230796
Anti-Hexokinase 1 (EPR10134(B)) abcam Cat# ab233837
Anti-Glucose 6 Phosphate Dehydrogenase
(EPR6292)
abcam Cat# ab231828
Anti-Peroxiredoxin 2/PRP (EPR5154) abcam Cat# ab227988
PE Anti-Glucose Transporter GLUT1 (EPR3915) abcam Cat# ab209449
Alexa Fluor 700 anti-human CD3 (SK7) Biolegend Cat# 344822; RRID:AB_2563420
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Brilliant Violet 421 anti-human CD14
(HCD14)
Biolegend Cat# 325628; RRID:AB_2563296
Brilliant Violet 510 anti-human CD19 (HIB19) Biolegend Cat# 302242; RRID:AB_2561668
BUV395 Mouse anti-human CD4 (SK3 (Leu3a)) BD Biosciences Cat# 563552; RRID:AB_2738275
APC-eFluor 780 anti-human CD8a (SK1) ThermoFisher Scientific Cat# 47-0087-42; RRID:AB_2016684
Brilliant Violet 785 anti-human CD56 (NCAM)
(5.1H11)
Biolegend Cat# 362550; RRID:AB_2566059
Brilliant Violet 650 anti-human CD45RO
(UCHL1)
Biolegend Cat# 304232; RRID:AB_2563462
Brilliant Violet 605 anti-human CD62L
(DREG-56)
Biolegend Cat# 304834; RRID:AB_2562130
Chemicals, peptides, and recombinant proteins
PepTivator EBV EBNA-1, human Miltenyi Biotec Cat# 130-093-613
PepTivator EBV LMP2A, human Miltenyi Biotec Cat# 130-093-615
PepTivator EBV BZLF1, human Miltenyi Biotec Cat# 130-093-611
Human AB serum Sigma Aldrich Cat# H4522
Brefeldin A Sigma Aldrich Cat# B5936
Sodium pyruvate Thermo Fisher Scientific Cat# BP356-100
L-Glutamine Thermo Fisher Scientific Cat# 25030081
Glucose Sigma Aldrich Cat# G7528
Methyl tert-butyl ether (MTBE) Biosolve Chemicals Cat# 13890602
Derivatization reagents for GC (MSTFA) Macherey-Nagel Cat# 701270.510
ULC/MS grade Acetonitrile Biosolve Chemicals Cat# 01204102
Acetic acid glacial ULC/MS Biosolve Chemicals Cat# 01074131
ULC/MS grade Water Biosolve Chemicals Cat# 23214102
Critical commercial assays
Seahorse XF Cell Mito Stress Test Kit Agilent Technologies Cat# 103015-100
Seahorse XF Base Medium Agilent Technologies Cat# 102353-100
Seahorse Calibrant Solution Agilent Technologies Cat# 100840-000
Seahorse XFe96 FluxPak Agilent Technologies Cat# 102416-100
RNeasy Plus Mini Kit Qiagen Cat# 74134
RevertAid HMinus First Strand cDNA Synthesis
Kit
Thermo Fisher Scientific Cat# K1632
TaqMan Gene Expression Assay Thermo Fisher Scientific Cat# 4331182
CD154 MicroBead Kit, human Miltenyi Biotec Cat# 130-092-658
CD3 MicroBeads, human Miltenyi Biotec Cat# 130-050-101
CD14 MicroBeads, human Miltenyi Biotec Cat# 130-050-201
LS columns Miltenyi Biotec Cat# 130-042-401
MS columns Miltenyi Biotec Cat# 130-042-201
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit Thermo Fisher Scientific Cat# L34957
Zombie UV Fixable Viability Kit Biolegend Cat# 423107
Zombie NIR Fixable Viability Kit Biolegend Cat# 423106
Fixation/Permeablization Kit BD Biosciences Cat# 554714; RRID:AB_2869008
eBioscience Foxp3 / Transcription Factor
Staining Buffer Set
ThermoFisher Scientific Cat# 00-5523-00
PE/Cy7 Conjugation Kit - Lightning-Link abcam Cat# ab102903
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PerCP/Cy5.5 Conjugation Kit - Lightning-
Link
abcam Cat# ab102911
PE/Atto 594 Conjugation Kit - Lightning-Link abcam Cat# ab269900




BD FACSDiva version 6.1.2 BD Biosciences RRID:SCR_001456
FlowJo 10.1 Treestar Inc., USA RRID:SCR_008520
GraphPad Prism 7 GraphPad Software Inc., USA RRID:SCR_002798
Wave Desktop 2.3 Agilent Technologies RRID:SCR_014526
R Version 4.0.5 R Project for Statistical Computing RRID:SCR_001905
Leco Chroma-TOF-GC Software v4.50.8.0 LECO N/A; https://www.leco.com/
product/chromatof-software
Python Programming Language 3.8.5 http://www.python.org/ RRID:SCR_008394
MatPlotLib 3.3.1 http://matplotlib.sourceforge.net RRID:SCR_008624
NumPy 1.19.1 http://www.numpy.org RRID:SCR_008633
Pandas 1.1.3 https://pandas.pydata.org RRID:SCR_018214
SciPy 1.5.2 http://www.scipy.org/ RRID:SCR_008058
Seaborn 0.11.0 https://seaborn.pydata.org/ RRID:SCR_018132
Statsmodel 0.12.0 http://www.statsmodels.org/ RRID:SCR_016074
Other
ACQUITY UPLC HSS T3 Column Waters Cat# 176001132






Requests for further information regarding resources and reagents used in this study should be directed to
the lead contact, Prof. Stefan Gold (stefan.gold@charite.de).Materials availability
This study did not generate new unique reagents.
Data and code availability
d Data on cellular metabolism measurements are available as a supplementary file (Data S1). Further data
reported in this paper will be shared by the lead contact upon request.
d No custom code was used in the analysis of the data.
d Any additional information required to reanalyze the data reported in this paper is available from the
lead contact upon request.EXPERIMENTAL MODEL AND SUBJECT DETAILS
Participants and clinical assessments
The study was approved by the Ethics Committee of Charité - Universitätsmedizin Berlin (EA1/096/15) and
conducted in accordance with relevant international, national and institutional guidelines (Helsinki
Declaration of 1975). All participants provided written informed consent and received remuneration for




Articlethe Department of Psychiatry, Charité - Universitätsmedizin Berlin. HC were recruited via the university
hospital’s study data bases as well as via print and online advertisements.
Summary and detailed patient characteristics can be found in Tables 1 and S2. MDD patients and HC were
matched pairwise for age, sex, smoking status, and BMI to minimize potential confounding effects of these
factors on biological variables of interest. Participants were excluded if they had a diagnosis of relevant
medical diseases (e.g., diabetes, cardiovascular diseases, autoimmune or infectious illnesses), currently
received immunomodulatory drugs (such as non-steroidal anti-inflammatory drugs (NSAIDs), glucocorti-
coids or antibiotics), or were vaccinated in the last three months. Pregnancy was also an exclusion criterion.
For the MDD group, patients had to have a clinician-confirmed diagnosis of MDD and a minimum antide-
pressant-free period of two weeks. Patients with comorbid psychiatric diagnoses other than mild-to-mod-
erate anxiety disorders were excluded. All HCs did not meet diagnostic criteria for any psychiatric disorder,
had a Montgomery Asberg Depression Rating Scale (MADRS) score <7 and no personal or family history of
affective disorders (first-degree relatives).
During the eligibility visit, participants underwent a detailed medical history assessment and a thorough
physical examination to assess body weight, height, waist/hip ratio, and blood pressure. In addition, blood
samples were taken for standard laboratory diagnostics, including: hemoglobin, hematocrit, MCV, MCH,
MCHC, RDW-CV, MPV, leukocyte, erythrocyte and platelet counts, differential blood count, CRP, HDL
and LDL cholesterol. Clinical diagnosis of MDD according to DSM-5 (American Psychiatric Association
and DSM-5 Task Force, 2013) was confirmed by two experienced board-certified psychiatrists (DP, CO)
as well as a structured interview (Mini-International Neuropsychiatric Interview = MINI). Clinician rating
of depression severity was obtained using theMADRS. MINI andMADRS were conducted by a trained rater
(HH). Self-report symptom severity was assessed by questionnaires for anxiety (Beck Anxiety Inventory,
BAI), depressive symptoms (Beck Depression Inventory II, BDI-II), and adverse childhood experiences
(Childhood Trauma Questionnaire, CTQ).METHOD DETAILS
Blood collection and isolation of PBMCs
Following an overnight fasting period of 12 h, peripheral blood was collected in heparinized tubes (BD,
Germany) between 8.00 a.m. and 9.30 a.m. PBMCs were isolated within 1 h of collection via density gradient
centrifugation. In short, diluted blood [1:1 with phosphate-buffered saline (PBS, Gibco, ThermoFisher Scientific,
Germany)] was layered on density medium (Biocoll, Biochrome, Germany), centrifuged, and the PBMC layer ob-
tained. PBMCswerewashed twice in PBS, counted, and resuspended in RPMI-1640+GlutaMaxmedium (Gibco,
ThermoFisher Scientific) supplemented with 25% heat-inactivated fetal calf serum (FCS) (Biochrome) and 10%
dimethylsulfoxide (DMSO) (Applichem GmbH, Germany) at 107 cells/ml for cryopreservation in liquid nitrogen.
Cryopreserved PBMCs were thawed in a 37C water bath for 2 min before being transferred into 10 ml of 37C
thawingmedium (RPMI-1640+GlutaMax+ 10%FCS). For antigen-reactivity experiments, FCSwas replacedwith
5%humanABserum (Sigma-Aldrich,Germany). Cellswere thenwashedwithmedium, counted andprepared for
subsequent experiments as described below.Blood cholesterol measurements
Serum high density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol levels were determined
by a clinically licensed diagnostic lab (Labor Berlin - Charité Vivantes GmbH, Germany).Metabolomics and lipidomics
General sample preparation and extraction for LC- and GC-MS: The sample preparation was performed
according to MetaSysX standard procedure, a modified protocol from Salem et al. (2016). Briefly, 50 ml
of serum from 22 MDD patients and corresponding matched HC was extracted by methyl-tert-butyl-ether
(MTBE)/methanol/water solvent system that separates molecules into aqueous and organic phase respec-
tively. After MTBE extraction fractions were collected to new tubes. Additional 150 ml of polar phase was
transferred to a tube for subsequent derivatization and GC-MS analysis. All the samples in new tubes
were dried down using a centrifugal evaporator and stored at 80C until LC-MS and GC-MS analysis.
Liquid phase chromatography and mass spectrometry (LC-MS) sample preparation. The dried sam-




ArticleLC-MS measurements. The samples were measured with a Waters ACQUITY Reversed Phase Ultra Per-
formance Liquid Chromatography (RP-UPLC) coupled to a Thermo-Fisher Exactive Plus mass spectrometer
(Thermo Fisher Scientific). C8 (100 mm 3 2.1 mm 3 1.7mm particles; Waters) and C18 (100 mm 3 2.1 mm 3
1.8mm particles; Waters) columns were used for the lipophilic and the hydrophilic measurements, respec-
tively. A 15 min gradient was used for separation of polar and lipophilic compounds. The mobile phases for
separation of polar and semi-polar compounds were 0.1% formic acid in H2O (buffer A) and 0.1% formic
acid in acetonitrile (buffer B). The chromatographic separation of these analytes was performed in the
following conditions: A 99% initial to 1 min, A 99% to A 60% to 11 min, A 60% to A 30% to 13 min and
A30% to A 1% to 15 min. The following mobile phases were used for lipids and lipophilic metabolites sep-
aration: 1% of 1M NH4Ac in 0.1% acetic acid (buffer A) and acetonitrile: isopropanol (7:3) containing 1% of
1M NH4Ac in 0.1% acetic acid (buffer B). The separation of lipids and lipophilic compounds was performed
with a step gradient from 45% initial to 1 min, 45% A to 25% A in 4 min, 25%–11% A in 11 min and 11%–0% A
in 15 min. Chromatograms were recorded in Full Scan MS mode (Mass Range [100–1500]). All mass spectra
were acquired in positive and negative mode.
LC-MS data processing and annotation. LC-MS RAW data files were extracted with the PeakShaper
-metaSysX GmbH internal software. Alignment and filtering of the LC-MS data were completed using in-
house software. An in-house metaSysX database of chemical compounds was used to match the features
detected in the LC-MS polar and non-polar platform. The metaSysX database contains the mass-to-charge
ratio and the retention time information of reference compounds measured at the same chromatographic
and spectrometric condition as samples measurements. A 5 ppm and 0.1 min deviation from the reference
compounds mass-to-charge-ratio and retention time respectively were used as matching criteria.
Gas chromatography andmass spectrometry (GC-MS) sample preparation. The derivatisation of the
metabolites for GC-MS analysis was performed according to previously described method (Lisec et al.,
2006). Briefly, the dried down samples were suspended in methoxy-hydrochlorid/pyridine solution and
incubated at 30C for 90 min followed by derivatization with N-methyl-N-trimethylsilyltrifluoroacetamide
(MSTFA) at 37C for 30 min.
GC-MS measurements. The samples were measured on an Agilent Technologies GC coupled to a Leco
Pegasus HTmass spectrometer which consists of an EI ionization source and a TOFmass analyzer. Column:
30 m DB35; starting temp: 85C for 2 min; gradient: 15C per min up to 360C.
GC-MS data processing and annotation. NetCDF files that were exported from the Leco Pegasus soft-
ware were imported into the ‘‘R’’ Bioconductor package TargetSearch (Cuadros-Inostroza et al., 2009) to
transform retention time to retention index (RI), to align the chromatograms, to extract the peaks, and
to annotate them by comparing the spectra and the RI to the Fiehn Library and to a user created library.
Annotation of peaks was manually confirmed in Leco Pegasus. Analytes were quantified using a unique
mass. Metabolites with a RT and a mass spectrum that did not have a match in the database were labeled
as unknown.
Data analysis. Feature intensities were log2-transformed and platform-wise subjected to measurement-
day- and sample-median-normalization as well as filtering (retention time, group-wise mean intensity).
Features with more than 20% missing values were discarded, the final dataset exhibited a total of 3511
features. Differential expression of features with respect to healthy and depressed groups was assessed
by means of a linear model. We added age, body mass index, sex, measurement day, smoking status
and thawing cycle as predictors to control for potential confounding. We controlled the false-discovery
rate for multiple comparisons platform-wise by the procedure of Benjamini & Hochberg (Benjamini and
Hochberg, 1995). Features were considered differentially expressed if the FDR-corrected p values with
respect to study groups was below a = 0.05. Associations of features with endpoints were quantified via
partial correlations. To this end, we predicted feature intensities and endpoints by a linear model
comprising the potential confounders age, body mass index, sex, measurement day, smoking status and
thawing cycle. We calculated Spearman’s rank correlation coefficient from the residuals. False-discov-
ery-rate was platform-wise controlled for multiple comparisons by the procedure of Benjamini & Hochberg.
Associations were considered significant if the FDR-corrected p values were below a = 0.05. Due to limited
availability of biomaterial from study participants BHC050, BHC053 BMDD010, BMDD013, BMDD023 and




ArticlePurification of T cells and monocytes
After thawing of cryopreserved PBMCs, CD3+ T cells and CD14+ monocytes were purified sequentially via
magnetic-activated cell sorting (MACS, Miltenyi Biotec, Germany). In brief, PBMCs were incubated with
20 ml of a-CD3 Microbeads (Miltenyi Biotec) and 80 ml of MACS buffer (0.5% BSA in AutoMACS rinsing so-
lution, both Miltenyi Biotec) per 107 cells for 15 min at 4C, washed and taken up in MACS buffer. Labeled
cells were then applied to an LS column (Miltenyi Biotec) for CD3+ T cell positive selection according to the
manufacturer’s instructions. Subsequently, CD14+ monocytes were purified from the negative fraction with
a-CD14 Microbeads (Miltenyi Biotec) in an analogous manner. In our hands, this procedure yields a cell
purity of 96.5 + 1.2% for T cells and 92.3 + 1.7% for monocytes.
Cellular respiration assay
Live cell metabolic assessments were conducted using the Cell Mito Stress Assay in a Seahorse XFe 96
Analyzer, optimized for use with cryopreserved primary human immune cells as described (Taenzer,
2019). Briefly, magnetically purified CD3+ T cells and CD14+ monocytes were rested for 2 h at 37C and
5% CO2 in RPMI1640 medium + GlutaMAX +10% FCS at a density of 2 3 10
6 cells/ml. Following a washing
step with Seahorse XF Base Medium (Agilent Technologies, USA) supplemented with 1 mM sodium
pyruvate, 2 mM L-glutamine (both ThermoFisher Scientific), 10 mM glucose (Sigma Aldrich) and adjusted
to pH 7.4. Cells were then transferred to a 96-well Seahorse cell culture plate in Seahorse medium at a
density of 4 3 105 cell per well in 3-5 replicates. The plate was incubated for 30 min at 37C in a non-
CO2 environment. The sensor cartridge was pre-hydrated with calibration buffer (Agilent Technologies)
for 4 h and the injection ports were filled with oligomycin, FCCP, rotenone/antimycin A at final assay
concentrations of 2 mM, 1 mM or 0.5 mM, respectively (Seahorse XF Cell Mito Stress Test Kit, Agilent
Technologies), or Seahorse medium. After an automated calibration process according to the manufac-
turer’s instructions the assay plate was measured in a Seahorse XFe 96 Analyzer (Agilent Technologies).
Key metabolic parameters were analyzed with Wave software (Agilent Technologies) (Figure S1). Matched
patient/HC pairs were measured on the same plate to avoid day-to-day variations between pairs.
Analysis of T cell phenotype
Antibody panels for flow cytometric analysis of T cell phenotype are depicted in Table S1. Thawed PBMCs
were incubated with a live/dead marker (Zombie NIR Fixable Viability Kit, Biolegend, UK) in PBS for 15 min
(together with the CCR7 antibody for the naive/memory T cell panel). Antibody premixes (see Table S1, all
Biolegend) were prepared in staining buffer [PBS +0.5% bovine serum albumin (Miltenyi Biotec) + 2 mM
EDTA (Promega, USA) + 0.02% sodium azide (Sigma-Aldrich)] and added to the cells for further 15 min.
Following a washing step, samples were resuspended in staining buffer and measured on a FACSCanto
II flow cytometer (BD, Germany). All flow cytometry data described (below) were analyzed using FlowJo
version 10.1 software (Treestar Inc., USA).
Analysis of inhibitory receptors and KLRG1
After thawing of PBMCs, each 53 105 cells were seeded into two wells of a 96-well round bottom plate and
rested over night at 37C, 5% CO2. The next day, the cells were stimulated with 10 mg/ml of a-CD3 antibody
and 1 mg/ml a-CD28 antibody or left unstimulated for 48 hours. Subsequently, PBMCs were harvested,
washed with PBS and stained with the respective staining mix (Table S1) for 15 min at room
temperature. Cells were washed and resuspended in staining buffer before flow cytometric analysis.
Analysis of EBV-reactive T cells
3-103 106 PBMCs were seeded at a density of 53 106 cells/cm2 in cell culture plates in RPMI1640medium+
GlutaMAX +5% human AB serum and incubated over night at 37C, 5% CO2. The next morning, cells were
stimulated with EBV antigens (EBNA-1 + LMP2a + BZLF1 peptide pools), MP65 peptide pool (all Miltenyi
Biotec, final concentration 0.6 nmol/ml/peptide) or left unstimulated for 7 h. To avoid downregulation of
the CD154 activation marker, a-CD40 antibody was added during the incubation period at 1 mg/ml
(Miltenyi Biotec). After 5 hours 2 mg/ml Brefeldin A (Sigma-Aldrich) was added for the last two hours of stim-
ulation. The cells were harvested and a small aliquot was removed for later FACS staining (= original frac-
tion; for all antibody panels see Table S1). PBMCs were washed with cold staining buffer and labeled with
a-CD154 Biotin + a-Biotin Microbeads according to the manufacturer’s instruction (CD154 MicroBead Kit,
Miltenyi Biotec) with a slight adaptation: The a-Biotin-antibody was added in combination with the surface




Articleand transferred to an equilibrated MS separation column attached to a strong magnet (Miltenyi Biotec).
The column was rinsed twice with Perm/Wash buffer (BD) and the intracellular staining mix was added
directly onto the column in Perm/Wash buffer. After a 12 min incubation time, the column was washed
again with Perm/Wash buffer and the enriched cells were eluted with staining buffer (= CD154 enriched
fraction). The CD154 enriched fraction was measured on a FACS Canto II flow cytometer (BD). For analysis,
the number of non-specifically activated background cells was subtracted from the positive signal. The fre-
quency of antigen-reactive T cells was calculated by dividing the absolute number of CD4+/CD154+ T cells
after enrichment by the absolute number of CD4+ T cells within total PBMCs before enrichment.Cell-specific gene expression by qPCR
CD3+ T cells and CD14+ monocytes were isolated from thawed PBMCs by magnetic-activated cell sorting,
as described above. RNA isolation was performed using Qiagen RNeasy Plus Mini Kit (Qiagen, Germany)
according to manufacturer’s instructions. Concentration and purity were measured with a NanoDrop spec-
trophotometer (NanoDrop 2000c, ThermoFisher Scientific). RNA was then transcribed to complementary
DNA (cDNA) using the RevertAid H Minus First Strand cDNA Synthesis Kit (ThermoFisher Scientific), ac-
cording to manufacturer’s instructions. cDNA amplification was carried out on a StepOne Real-Time
PCR system (Applied Biosystems, Germany) using TaqMan Gene Expression Assays (ThermoFisher Scien-
tific) for TNF (Hs01113624_g1), SLC2A1 (Hs00892681_m1) (encoding GLUT1) and CPT1a (Hs00912671_m1).
All RT-qPCR reactions were performed in triplicates with matched control and patient samples always on
the same plate. Results are given as relative gene expression (normalized to the geometric mean of the two
housekeeping genes, TATA Box Binding Protein (TBP; HS00427620_m1) and Importin 8 (IPO8;
Hs00183533_m1).Met-flow
Met-Flow, a flow cytometry-based method capturing the metabolic state of immune cells by targeting key
proteins and rate-limiting enzymes across multiple pathways (Ahl et al., 2020), was used in a subset of n = 5
MDD cases and n = 5 matched healthy controls. The antibody panel used for flow cytometry-based meta-
bolic readouts is provided in Table S1. The key metabolic proteins CPT1a, GLUT1, PRDX2, G6PD, IDH2 and
HK1 were chosen for analysis.
PBMCs were thawed and 1.53 106 cells were seeded into round bottom 96 well plates at a density of 0.53
106 cells/well in RPMI1640medium +10% FCS and incubated for 2 hrs at 37C, 5% CO2. Cells were then pre-
stained with a Live/Dead marker (Zombie UV Fixable Viability Kit, Biolegend) in PBS for 20 min at RT in the
dark. Following a washing step with FACS buffer (PBS + 2 % BSA), surface staining antibody mix prepared
in PBS was added to the cells and incubated for 30 min at RT protected from light. After a washing step
(Perm/wash solution, Invitrogen eBioscience Foxp3/Transcription Factor Staining Buffer Set, Thermo
Fisher Scientific), cells were fixed with fixation/permeabilization solution (Invitrogen eBioscience Foxp3/
Transcription Factor Staining Buffer Set, Thermo Fisher Scientific) for 30 min, followed by intracellular stain-
ing in permeabilization buffer for 30 min at RT in the dark. PBMCs were washed once more with Perm/wash
solution, resuspended in FACS buffer and measured on a FACS Fortessa flow cytometer (BD).QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis
Continuous variables were analyzed with Wilcoxon signed-rank test based on the pairwise matching of
MDD patients and HC (for age, sex, smoking, and BMI). Dichotomous variables were analyzed with McNe-
mar’s test.
Planned and pre-specified primary analyses used the standard, unadjusted alpha level of 0.05 for each var-
iable of interest (each systemic metabolic marker, each cellular respiration read-out, and all cell subset fre-
quencies obtained from immunophenotyping). In order to corroborate these results, we also conducted
secondary analyses adjusting for multiple comparisons per group of variables of interest using Bonferroni
adjustments (i.e. an alpha level of 0.0125 for the four systemic markers LDL/HDL ratio, WHR, systolic and
diastolic blood pressure, an alpha level of 0.0071 for the seven parameters of cellular respiration in
T cells and monocytes, and an alpha level of 0.005 for ten MADRS items, respectively). Gene expression
analyses were considered exploratory and not adjusted for multiple comparisons. Statistical details18 iScience 24, 103312, November 19, 2021
